The third decade marks an important milestone for Pharex as a brand and company. In recent years, significant changes have occurred, with the company joining RiteMED and UNILAB for a bigger endeavor.
February 18, 2019
In partnership with the Philippine Heart Association (PHA), Pharex launched its newest hypertension product, Pharex Irbesartan. It is an Angiotensin II Receptor Blocker, which is indicated for patients with hypertension and diabetic nephropathy. It is available in 150 mg and 300 mg tablets and is the first unibranded Irbesartan that is 30% more affordable than the innovator.
The launch started with the welcome remarks of Pharex President, Mr. Tomas Marcelo Agana III, followed by the opening remarks of PHA President, Dr. Jorge Sison. In his lecture, Pambansang Samahan sa Sikolohiyang Pilipino (PSSP) Professor Jay A. Yacat discussed the roles of illness beliefs, perceptions and practices in medication adherence among Filipino patients with hypertension. This is the first-ever research collaboration with PSSP to uncover attitudes towards compliance to hypertensive medication.
There was an interactive discussion where three cardiologist-panelists shared their thoughts and clinical experience concerning hypertensive patients who have difficulty adhering to medication and the importance of doctor and patient relationship.
Pharex Irbesartan It is the newest addition to the hypertension portfolio of Pharex. Partner doctors from the Family Medicine, Internal Medicine and General Practitioners also graced the event.